Parkinson's disease

[The University of Texas Health Science Center at Houston (Newswise, Inc.)] A Phase II clinical trial to assess mesenchymal adult stem cells as a disease-modifying therapy for Parkinson's disease has been launched at The University of Texas Health Science Center at Houston

[MedRhythms (PR Newswire, LLC)] MedRhythms has announced the initiation of a multi-site clinical trial, in collaboration with Boston University, of its pipeline asset MR-005 in Parkinson's disease as well as the expansion of the company's pipeline into aging with the development of its Aging Scientific Advisory Board.

[APL Bioengineering] The authors describe sex-related differences in neurodegenerative diseases and the blood–brain barrier, whose dysfunction is linked to neurodegenerative disease development and progression.

[Analyst] Scientists developed a novel electrochemical sensing approach capable of detecting dopamine, the main biomarker in Parkinson's disease, within the highly complex cell culture matrix of human midbrain organoids in a non-invasive and label-free manner.

[Alterity Therapeutics, Ltd.] Alterity Therapeutics, Ltd. announced the award of a grant from The Michael J. Fox Foundation for Parkinson's Research to determine optimal dosing of its lead drug candidate ATH434 for Parkinson's disease based on imaging of brain iron.

[BlueRock Therapeutics (PR Newswire, Inc.)] BlueRock Therapeutics, in collaboration with Memorial Sloan Kettering Cancer Center, announced that the US FDA has cleared their Investigational New Drug application to proceed with a Phase I study in patients with advanced Parkinson's disease (PD). This is the first trial in the US to study pluripotent stem cell-derived dopaminergic neurons in patients with Parkinson's disease.